Ion Beam Applications SA (IBAB)

Currency in EUR
15.70
-0.36(-2.24%)
Closed·
IBAB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
15.5816.10
52 wk Range
9.9017.76
Key Statistics
Prev. Close
16.06
Open
15.94
Day's Range
15.58-16.1
52 wk Range
9.9-17.76
Volume
17.27K
Average Volume (3m)
29.98K
1-Year Change
30.1824%
Book Value / Share
4.37
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IBAB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
17.63
Upside
+12.26%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility

Ion Beam Applications SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 17.63
(+12.26% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Kepler Cheuvreux
Hold12.00-23.57%-Maintain30/12/2025

Ion Beam Applications SA Earnings Call Summary for Q2/2026

  • IBA reported H1 2026 revenue of EUR 324M and adjusted EBIT of EUR 17.6M, returning to net profit of EUR 9.3M with gross margin expanding to 33.7%.
  • Equipment orders surged 64% to EUR 176M while backlog held steady at EUR 1.6B; stock rose 3.34% to $16.70, near 52-week high of $17.76.
  • Company reaffirmed full-year 2026 adjusted EBIT guidance of at least EUR 32M, maintaining long-term targets of 40% gross margin and 10% EBIT margin.
  • Proton therapy business strengthened with 93 operational sites planned and 50% China market share; ConformalFLASH received FDA approval in June.
  • Net debt rose to EUR 81M from year-end; management expects cash flow improvement in H2 2027 as Spanish proton therapy projects deliver revenue.
Last Updated: 28/08/2026, 12:06 am
Read Full Transcript

Earnings

Latest Release
27/08/2026
EPS / Forecast
0.32 / --
Revenue / Forecast
323.7M / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.85%
Dividend Yield
1.09%
Industry Median 1.51%
Annualised payout
0.18
Paid unevenly
5-Years Growth
+4.56%
Growth Streak

IBAB Income Statement

Compare IBAB to Peers and Sector

Metrics to compare
IBAB
Peers
Sector
Relationship
P/E Ratio
19.0x21.4x−0.4x
PEG Ratio
-0.910.00
Price/Book
3.7x2.2x2.6x
Price / LTM Sales
0.7x2.3x3.1x
Upside (Analyst Target)
18.6%17.1%49.0%
Fair Value Upside
Unlock9.9%7.1%Unlock

Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation and energy switching while the gantry is rotating; Proteus ONE, a compact proton therapy system transforming cancer treatment; Proteus PLUS, a proton therapy solution for cancer centers; and dosimetry solutions that includes radiation therapy; medical imaging; and QUASAR that offers a portfolio of sophisticated phantoms supporting MR guided radiation therapy, motion management, surface guided radiation therapy, geometric distortion analysis, and machine targeting solutions. It also offers radio pharma solutions, including radioisotopes, cyclotrons, and radiochemistry, as well as other integrated and industrial solutions, and services. In addition, the company is involved in construction of proton therapy, and other accelerators equipment and installation services; and operation and maintenance services, as well as sales a license for intellectual property. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Employees
2039
Market
Belgium

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.36M14.98%69.96M
Other Institutional Investors
15.01M51.60%241.04M
Public Companies & Retail Investors
9.72M33.43%156.16M
Total
29.09M100.00%467.16M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Sustainable Anchorage Srl21.33%6,204,66899,647
Vallgesa Limited7.01%2,040,54132,771

People Also Watch

81.60
SYENS
-0.37%
29.35
EVSB
+1.56%
32.50
EQSE
-0.15%
104.20
SIFB
-0.95%
5.67
FFARM
+0.18%

FAQ

What Is the Ion Beam Applications (IBAB) Stock Price Today?

The Ion Beam Applications stock price today is 15.70 EUR.

What Stock Exchange Does Ion Beam Applications Trade On?

Ion Beam Applications is listed and trades on the Brussels Stock Exchange.

What Is the Stock Symbol for Ion Beam Applications?

The stock symbol for Ion Beam Applications is "IBAB."

Does Ion Beam Applications Pay Dividends? What’s The Current Dividend Yield?

The Ion Beam Applications dividend yield is 1.09%.

What Is the Ion Beam Applications Market Cap?

As of today, Ion Beam Applications market cap is 467.16M EUR.

What Is Ion Beam Applications's Earnings Per Share (TTM)?

The Ion Beam Applications EPS (TTM) is 0.85.

From a Technical Analysis Perspective, Is IBAB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Ion Beam Applications Stock Split?

Ion Beam Applications has split 1 times.

How Many Employees Does Ion Beam Applications Have?

Ion Beam Applications has 2039 employees.

What is the current trading status of Ion Beam Applications (IBAB)?

As of 03/09/2026, Ion Beam Applications (IBAB) is trading at a price of 15.70 EUR, with a previous close of 16.06 EUR. The stock has fluctuated within a day range of 15.58 EUR to 16.10 EUR, while its 52-week range spans from 9.90 EUR to 17.76 EUR.

What Is Ion Beam Applications (IBAB) Price Target According to Analysts?

The average 12-month price target for Ion Beam Applications is 17.63 EUR, with a high estimate of 20.5 EUR and a low estimate of 12 EUR. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +12.26% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.